Australia's Emyria climbs as preclinical study for neurological disorder starts
19/09/2022 05:56
** Shares of Emyria Ltd EMD.AX rise as much as 8.9% to
A$0.245, on track for best day since Aug. 18, if gains hold
** Biopharmaceutical developer says it has commenced
U.S.-based, MDMA-inspired new drug discovery program for the
treatment of neurological disorders, in partnership with
research organisation PsychoGenics urn:newsml:reuters.com:*:nASX94RC4S
** Says MDMA drug is showing promise as an adjunct to
psychotherapy for the treatment of major unmet mental health
needs
** Says PsychoGenics will use its proprietary SmartCube
platform to study novel compounds from co's preclinical program
** Stock down 41.6% so far this year, as of last close
(Reporting by Poonam Behura in Bengaluru)
((Poonam.Behura@thomsonreuters.com;))